NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death

S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth

(2018) Patrick Casara et al.   Oncotarget

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

(2017) Matthew S. Davids et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

(2017) Ahmet Zehir et al.   NATURE MEDICINE

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

(2017) Avi Ashkenazi et al.   NATURE REVIEWS DRUG DISCOVERY

Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer

(2017) Delphine Merino et al.   Science Translational Medicine

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism

(2016) M. A. Anderson et al.   BLOOD

A BH3 Mimetic for Killing Cancer Cells

(2016) Douglas R. Green   CELL

BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics

(2016) R. S. Soderquist et al.   MOLECULAR CANCER THERAPEUTICS

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

(2016) Andrew W. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

The BCL-2 protein family, BH3-mimetics and cancer therapy

(2015) A R D Delbridge et al.   CELL DEATH AND DIFFERENTIATION

Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials

(2015) David M. Hyman et al.   DRUG DISCOVERY TODAY

Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1

(2015) L Li et al.   LEUKEMIA

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

(2015) Joel D. Leverson et al.   Science Translational Medicine

Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)

(2015) D C Phillips et al.   Blood Cancer Journal

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

(2015) A. N. Hata et al.   Cancer Discovery

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B

(2012) R W Rooswinkel et al.   Cell Death & Disease

Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia

(2011) J. M. Tromp et al.   CLINICAL CANCER RESEARCH

Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737

(2011) K. M. Lucas et al.   CLINICAL CANCER RESEARCH

Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA

(2010) Barbora Brodská et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Bim Upregulation by Histone Deacetylase Inhibitors Mediates Interactions with the Bcl-2 Antagonist ABT-737: Evidence for Distinct Roles for Bcl-2, Bcl-xL, and Mcl-1

(2009) S. Chen et al.   MOLECULAR AND CELLULAR BIOLOGY

Noxa: at the tip of the balance between life and death

(2009) C Ploner et al.   ONCOGENE